EUS-FNA can help doctors manage certain pancreatic lesions more effectively

September 1, 2016

An endoscopic procedure can improve the outlook for patients with a fairly common type of pancreatic lesion that is challenging to manage and that, if left untreated, can progress to cancer, according to a study in the September issue of GIE: Gastrointestinal Endoscopy, the peer-reviewed journal of the American Society for Gastrointestinal Endoscopy (ASGE).

Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) are complicated to treat. They are located in the pancreas, but their position in the branch ducts makes them difficult to access. So the benefit of accessing these branches for resection of (removing by cutting) the lesion or must be weighed against the risks. IPMNs in the branch ducts are thought to be less likely to progress to cancer than those in the main duct of the pancreas.

According to the study, "Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes," endoscopic ultrasound with (EUS-FNA) increasingly has been used to determine characteristics of these neoplasms. But the benefit of doing so has not been well described.

EUS is a technique using sound waves known as ultrasound during an to look at or through the wall of the gastrointestinal tract. Under continuous, real-time ultrasound guidance, a thin needle can be advanced into these structures to draw out (aspirate) fluid from the tissue. The cells obtained from the FNA can be analyzed under a microscope for abnormalities such as cancer.

In order to choose the most beneficial approach, doctors may rely not only on the size, but also on specific features, of the lesions in order to choose the best treatment approach. The study authors sought to determine the overall impact of this procedure on the identifying worrisome lesions and referring patients for surgery, compared with imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI).

This retrospective study looked at patients with established BD-IPMNs, evaluated in a tertiary care referral center between 2001 and 2013. The researchers looked for associations between worrisome features (such as signs of bleeding or nodules) and malignancy in the lesions, as well as effectiveness of endoscopic ultrasound-fine (EUS-FNA) for diagnosing malignant BD-IPMNs. The study also looked at recurrence of lesions and long-term outcomes of BD-IPMN patients who underwent a surgical resection.

Of 364 patients with BD-IPMN, 229 underwent imaging surveillance and 135 went on to have surgery to remove the lesion (resection). The study focused on these 135 patients. With CT/MRI, worrisome findings were similar between the benign and malignant groups, but main pancreatic duct (MPD) dilation (5-9 mm) was more frequently identified in malignant lesions.

On EUS-FNA, suspicious features of the lesions were more frequently detected in the malignant group compared with CT/MRI. Mural (in the wall) nodules, specifically, identified by EUS were missed by CT/MRI in 28% of the malignant group.

Patients with malignant lesions had a higher risk of any IPMN recurrence during a mean follow-up period of 10.9 years. Benign IPMN recurrence was observed in some patients up to eight years after resection.

The authors concluded that there is incremental value of EUS-FNA over imaging in identifying malignant BD-IPMNs, and the procedure is particularly beneficial for who have lesions without obvious worrisome features and those with smaller cysts.

Explore further: Study sheds light on true risk for pancreatic cancer in patients with cysts

More information: See the video interview with the author www.giejournal.org/

See the ASGE media backgrounder on EUS-FNA www.asge.org/press/press.aspx?id=11558

Related Stories

Study sheds light on true risk for pancreatic cancer in patients with cysts

July 11, 2016
A look back at more than half a million patient records has established that patients with pancreatic cysts have a significantly higher overall risk of pancreatic cancer compared to those without such cysts, according to ...

Team finds cancer biopsies do not promote cancer spread

January 9, 2015
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients ...

Researchers discover biological markers associated with high-risk pancreatic lesions

February 2, 2015
Pancreatic cancer affects approximately 46,000 people each year in the United States and ranks fourth among the leading causes of cancer-related deaths. Only about 6 percent of individuals with pancreatic cancer will live ...

Recommended for you

How hepatitis C hides in the body

October 13, 2017
The Hepatitis C (HCV) virus is a sly enemy to have in one's body. Not only does it manage to make itself invisible to the immune system by breaking down communication between the immune cells, it also builds secret virus ...

Largest study yet of malaria in Africa shows historical rates of infection

October 12, 2017
(Medical Xpress)—A team of researchers with members from the Kenya Medical Research Institute, the University of Oxford and the University of KwaZulu-Natal has conducted the largest-ever study of the history of malaria ...

Promising new target for treatment of psoriasis is safe, study shows

October 11, 2017
A protein known to play a significant role in the development of psoriasis can be prevented from functioning without posing a risk to patients, scientists at King's College London have found.

Norovirus evades immune system by hiding out in rare gut cells

October 11, 2017
Noroviruses are the leading cause of non-bacterial gastroenteritis in the world and are estimated to cause 267 million infections and 20,000 deaths each year. This virus causes severe diarrhea, nausea, and stomach pain.

Research reveals how rabies can induce frenzied behavior

October 11, 2017
Scientists may finally understand how the rabies virus can drastically change its host's behavior to help spread the disease, which kills about 59,000 people annually.

Experimental Ebola vaccines elicit year-long immune response

October 11, 2017
Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.